Cellebrite DI Ltd. (NASDAQ:CLBT) is True Wind Capital Management L.P.'s Largest Position

True Wind Capital Management L.P. raised its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 18.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,861,007 shares of the company's stock after acquiring an additional 2,130,386 shares during the period. Cellebrite DI comprises 87.1% of True Wind Capital Management L.P.'s holdings, making the stock its biggest holding. True Wind Capital Management L.P. owned approximately 6.73% of Cellebrite DI worth $305,358,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its position in Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company's stock worth $94,586,000 after buying an additional 3,239,307 shares during the period. Principal Financial Group Inc. bought a new position in shares of Cellebrite DI during the third quarter valued at $23,402,000. Lord Abbett & CO. LLC acquired a new position in shares of Cellebrite DI during the third quarter worth $11,523,000. Summit Partners Public Asset Management LLC bought a new stake in shares of Cellebrite DI in the third quarter worth $9,274,000. Finally, Telemark Asset Management LLC acquired a new stake in Cellebrite DI in the third quarter valued at $6,736,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT traded up $0.31 during trading on Wednesday, reaching $18.34. 741,864 shares of the stock were exchanged, compared to its average volume of 1,107,079. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of -13.19, a price-to-earnings-growth ratio of 4.27 and a beta of 1.47. The stock has a fifty day moving average of $22.14 and a two-hundred day moving average of $19.69. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30.

Remove Ads

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Sell-side analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on CLBT shares. Lake Street Capital upped their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Craig Hallum upped their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.